Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2017-06-26 | Scott A. Smith has served in various management capacities with Celgene Corporation since 2008, including as President, Inflammation and Immunology since August 2014. Based on Mr. Smith’s extensive management experience in the pharmaceutical industry, our Board believes that Mr. Smith has the appropriate set of skills to serve as a member of the Board. The compensation committee currently consists of Scott A. Smith (chair), Joseph A. Akers and M. David MacFarlane. Scott A. Smith 2016 Total Compensation $32,083. |
| 2018-07-02 | Scott A. Smith served in various management capacities with Celgene Corporation from 2008 until April 2018. The compensation committee currently consists of Scott Smith (chair), Joseph A. Akers and M. David MacFarlane. The following table summarizes compensation that our non-employee directors earned during 2017 for services as members of our Board. Scott A. Smith earned $77,752 in total compensation. |
| 2018-12-20 | Scott A. Smith Fees Earned or Paid in Cash ($): $52,500 Total ($): $52,500 |
| 2019-11-20 | Scott A. Smith (57) has served since September 2018 as President of BioAlta, LLC. ... The compensation committee currently consists of Scott A. Smith (chair), Joseph A. Akers and M. David MacFarlane, each of whom meets the independence requirements and standards currently established by Nasdaq. |
| 2020-01-31 | Scott A. Smith(6) Represents shares issuable upon exercise of outstanding options. |
| 2020-05-22 | Name and Address of Beneficial Owner(1) Scott A. Smith(9) |
| 2020-11-02 | Scott A. Smith(9) Represents shares issuable upon exercise of outstanding options. |
Data sourced from SEC filings. Last updated: 2026-02-03